<DOC>
	<DOCNO>NCT00473486</DOCNO>
	<brief_summary>The majority patient advance NSCLC treat standard platinum base chemotherapy regimens ultimately develop disease progression . Active therapy improve toxicity profile clearly need setting . The primary objective trial ass toxicity profile determine effect progression free survival time progression patient advance NSCLC treat sorafenib addition carboplatin pemetrexed .</brief_summary>
	<brief_title>Study Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed Carboplatin Plus Minus Sorafenib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm NSCLC Locally advance ( stage IIIB malignant pleural pericardial effusion ) metastatic ( stage IV ) NSCLC No prior systemic chemotherapy Prior local radiotherapy allow complete least 3 week prior first dose study medication ; also concomitant palliative radiotherapy exist bone lesion pain control allow Prior surgery allow perform least 4 week prior first dose study medication patient fully recover . Must measurable disease least one lesion long diameter measure ≥ 2 cm conventional technique ≥ 1 cm spiral CT Age ≥18 year old ECOG performance score ( PS ) 01 Life expectancy least 12 week Adequate bone marrow , renal hepatic function hemoglobin ≥ 9.0 g/dl absolute neutrophil count ≥1,500/mm3 platelet count ≥ 100,000/mm3 total bilirubin ≤ 1.5 time upper limit normal ALT AST ≤ 2.5 time upper limit normal ( ≤ 5 x upper limit normal patient liver involvement ) INR ≤ 1.5 aPTT within normal limit serum creatinine ≤ 1.5 upper limit normal Patients creatinine clearance ≥ 45 mL/min Not pregnant nursing patient Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment Women childbearing potential men must agree use adequate contraception ( barrier method birth control ) prior study entry duration study participation . Men use adequate birth control least six month last administration sorafenib Signed inform consent prior study specific procedure Compliance geographic proximity allow adequate followup Any prior systemic anticancer therapy include cytotoxic therapy , target agent , experimental therapy ( treatment within last 30 day drug receive regulatory approval indication time study enrollment ) , adjuvant , neoadjuvant therapy NSCLC Any participation clinical trial 30 day prior study entry concomitantly study Cardiac disease : Congestive heart failure &gt; class II NYHA . Patients must unstable angina ( angina symptom rest ) newonset angina ( begin within last 3 month ) myocardial infarction within past 6 month Cardiac ventricular arrhythmia require antiarrhythmic therapy Uncontrolled hypertension define systolic blood pressure &gt; 150 mm Hg diastolic pressure &gt; 90 mm Hg , despite optimal medical management Documented brain metastasis ( unless patient &gt; 6 month definitive therapy brain metastasis , negative imaging study within 4 week study entry corticosteroid least 4 week study enrolment ) . Brain imaging ( CT scan/MRI ) require symptomatic patient rule brain metastasis , require asymptomatic patient . Patients seizure disorder require medication ( steroids antiepileptic ) Known HIV infection chronic hepatitis B C Active clinically serious infection &gt; CTCAE Grade 2 Presence clinically significant thirdspace fluid collection , example , ascites pleural effusion control drainage procedure prior study enrolment Pulmonary hemorrhage/bleeding event &gt; = CTCAE Grade 2 within 4 week first dose study drug Any hemorrhage/bleeding event &gt; =Grade 3 within 4 week first dose study drug Evidence history bleed diathesis coagulopathy Therapeutic anticoagulation vitamin K antagonists phenprocoumon , warfarin , heparins heparinoids . Low dose anticoagulation permit Serious , nonhealing wound , ulcer , bone fracture Major surgery , open biopsy significant traumatic injury within 4 week first dose study drug Known suspect allergy sorafenib , carboplatin pemetrexed Previous current cancer distinct primary site histology NSCLC except cervical cancer insitu , treat basal cell carcinoma , superficial bladder tumor ( Ta Tis ) cancer curatively treat &gt; 3 year prior study entry Substance abuse , medical , psychological social condition may interfere patient participation study Significant weight loss ( &gt; equal 10 % body weight preceeding 6 week ) Inability interrupt aspirin nonsteroidal antiinflammatory agent , aspirin dose ≤ 1.3 gram per day , 5day period ( 8day period longacting agent , piroxicam ) Inability unwillingness take folic acid , vitamin B12 supplementation corticosteroid Recent ( within 30 day enrolment ) concurrent yellow fever vaccination Serious concomitant systemic disorder , opinion investigator , would compromise patient 's ability adhere protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>